Hell J Nucl Med
-
Brown tumor is one of the skeletal manifestations of hyperparathyroidism. It is a benign but locally aggressive bone lesion and its differential diagnosis with giant cell containing skeletal tumors or metastases may be complicated. We present a male patient with chronic renal failure who was initially misdiagnosed as having a giant-cell rich neoplasm of bone in his right thumb. ⋯ Parathyroid hyperplasia was finally diagnosed with (99m)Tc-methoxyisobutylisonitrile (MIBI) parathyroid scintigraphy. Fluorine-18-FDG avid lytic lesions were attributed to hyerparathyroidism associated brown tumors instead of multiple metastases. In conclusion, we present a patient with chronic renal insufficiency, who suffered from secondary and later from tertiary HPT with polyostotic brown tumors, which were best shown by the (18)F-FDG PET/CT than by the (99m)Tc-MDP or the (99m)Tc-MIBI scans.
-
Historical Article
Medical practice in the ancient Asclepeion in Kos island.
Asclepius was called "a great doctor for every disease". Asclepius was born in Trikala, Thessaly, in the middle of Greece, where the first Asclepeion was established. Patients coming to the Asclepeia were first taking cleaning baths and then entered the main Asclepeion, where they were examined by priests-therapists and were accommodated in certain areas-rooms of the Asclepeion. ⋯ Recent excavations in the area in order to find and restore the old Asclepeion started in 1902. Now Asclepeion is partly restored. In conclusion, it is suggested that Hippocratic medicine, as practiced in the Asclepeion of the island of Kos, using psychosomatic means of treatment in a green natural environment was effective for many diseases at that time but also inspired modern medicine and as an example a large university institution is now under constructions based on the above ideals.
-
Biography Historical Article
Abass Alavi. A distinguished physician scientist and a pioneer in molecular imaging.
Abass Alavi is a world renowned physician-scientist and has made substantial contributions to development and translation of modern imaging techniques to the day-to-day practice of medicine. Among his accomplishments, the introduction of fluorine-18-fluorodeoxyglucose ((18)F-FDG )-positron emission tomography (PET) has truly revolutionized the field of medicine worldwide. ⋯ He has received many awards for his outstanding contributions to the field of molecular imaging. Currently, he is actively involved in conducting research on a full time basis.
-
Sarcoidosis is a multisystem granulomatous disease of unknown etiology. The diagnosis is based on clinical and radiographic findings as well as by histopathological findings. ⋯ Positron emission tomography with fluorine-18-fluorodeoxyglucose ((18)F-FDG) has shown effectiveness in detecting occult disease and assessing disease activity during treatment. This review article provides an overview of the applications of PET/computed tomography and PET/ magnetic resonance imaging for evaluation of patients with sarcoidosis.
-
Comparative Study Clinical Trial
Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
The objectives of this study was to study the diagnostic efficacy of 3'-deoxy-3'-fluorine-18-fluorothymidine ((18)F-FLT) and of 2'-deoxy-2'-(18)F-fluoro-d-glucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for response evaluation following three weeks treatment by epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in non small cell lung cancer (NSCLC) patients. Fifteen patients of advanced stage (IIIB-IV) NSCLC planned for oral 1st or 2nd/3rd line EGFR-TKI treatment were enrolled in the study. Baseline, prior to treatment, and follow-up after three weeks, (18)F-FLT and (18)F-FDG PET/CT imaging was performed in all patients. ⋯ In conclusion, in both responders and in non responders, patients with NSCLC treated for 3 weeks by EGFR-TKI, both OS and PFS were better predicted by (18)F -FDG SULpeak than by (18)F -FLT SULpeak. Although, the difference was only borderline, yet, (18)F -FDG SULpeak was a better predictor of OS compared to TLG values. However, to validate these findings, studies need to be carried in a larger number of patients.